These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 33421158)

  • 1. The Use of Rifaximin in Patients With Cirrhosis.
    Caraceni P; Vargas V; Solà E; Alessandria C; de Wit K; Trebicka J; Angeli P; Mookerjee RP; Durand F; Pose E; Krag A; Bajaj JS; Beuers U; Ginès P;
    Hepatology; 2021 Sep; 74(3):1660-1673. PubMed ID: 33421158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
    Bajaj JS
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.
    Vlachogiannakos J; Viazis N; Vasianopoulou P; Vafiadis I; Karamanolis DG; Ladas SD
    J Gastroenterol Hepatol; 2013 Mar; 28(3):450-5. PubMed ID: 23216382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and future pharmacological therapies for managing cirrhosis and its complications.
    Kockerling D; Nathwani R; Forlano R; Manousou P; Mullish BH; Dhar A
    World J Gastroenterol; 2019 Feb; 25(8):888-908. PubMed ID: 30833797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
    Patel VC; Lee S; McPhail MJW; Da Silva K; Guilly S; Zamalloa A; Witherden E; Støy S; Manakkat Vijay GK; Pons N; Galleron N; Huang X; Gencer S; Coen M; Tranah TH; Wendon JA; Bruce KD; Le Chatelier E; Ehrlich SD; Edwards LA; Shoaie S; Shawcross DL
    J Hepatol; 2022 Feb; 76(2):332-342. PubMed ID: 34571050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis.
    Zeng X; Sheng X; Wang PQ; Xin HG; Guo YB; Lin Y; Zhong JW; He CZ; Yin J; Liu TT; Ma WJ; Xiao X; Shi PM; Yuan ZL; Yang L; Ma X; Xu JM; Shen XZ; Yang CQ; Zhu X; Lv NH; Xie WF
    Hepatol Int; 2021 Feb; 15(1):155-165. PubMed ID: 33385299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Complications of liver cirrhosis].
    Appenrodt B; Trebicka J; Sauerbruch T
    Dtsch Med Wochenschr; 2011 Aug; 136(31-32):1601-4. PubMed ID: 21809252
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers.
    Madsen BS; Havelund T; Krag A
    Adv Ther; 2013 Jul; 30(7):659-70. PubMed ID: 23881723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
    Kang SH; Lee YB; Lee JH; Nam JY; Chang Y; Cho H; Yoo JJ; Cho YY; Cho EJ; Yu SJ; Kim MY; Kim YJ; Baik SK; Yoon JH
    Aliment Pharmacol Ther; 2017 Nov; 46(9):845-855. PubMed ID: 28836723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis.
    Kamal F; Khan MA; Khan Z; Cholankeril G; Hammad TA; Lee WM; Ahmed A; Waters B; Howden CW; Nair S; Satapathy SK
    Eur J Gastroenterol Hepatol; 2017 Oct; 29(10):1109-1117. PubMed ID: 28763340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Rifaximin in Spontaneous Bacterial Peritonitis Prevention.
    Oliver A; Wong M; Sanchez C
    South Med J; 2018 Nov; 111(11):660-665. PubMed ID: 30392000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
    Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
    J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis.
    Garcia-Tsao G
    Dig Dis; 2016; 34(4):382-6. PubMed ID: 27170392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial.
    Kulkarni AV; Avadhanam M; Karandikar P; Rakam K; Gupta A; Simhadri V; Premkumar M; Zuberi AA; Gujjarlapudi D; Narendran R; Shaik S; Sharma M; Iyengar S; Alla M; Venishetty S; Reddy DN; Rao PN
    Am J Gastroenterol; 2024 May; 119(5):864-874. PubMed ID: 37942950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis.
    Shamsaddini A; Gillevet PM; Acharya C; Fagan A; Gavis E; Sikaroodi M; McGeorge S; Khoruts A; Albhaisi S; Fuchs M; Sterling RK; Bajaj JS
    Gastroenterology; 2021 Aug; 161(2):508-521.e7. PubMed ID: 33857456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complications of cirrhosis.
    Rahimi RS; Rockey DC
    Curr Opin Gastroenterol; 2012 May; 28(3):223-9. PubMed ID: 22343347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing the development of varices in cirrhosis.
    Garcia-Tsao G
    J Clin Gastroenterol; 2007; 41 Suppl 3():S300-4. PubMed ID: 17975480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
    Flamm SL
    Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
    Elfert A; Abo Ali L; Soliman S; Ibrahim S; Abd-Elsalam S
    Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1450-1454. PubMed ID: 27512927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.